American biopharmaceutical company in Boston, Massachusetts, founded in 2003 and taken private in 2022, which works in bone health and endocrine disease. Sells abaloparatide, a parathyroid hormone related peptide analogue for osteoporosis, as an injection and in a transdermal form, runs its own clinical development and trials, and handles regulatory affairs, medical affairs and pharmacovigilance for its products.
コメントはありません。
評価とコメントを残す